本帖最后由 老马 于 2013-3-13 13:43 编辑
+ j8 r# T) }3 t+ J- W" g# i" J4 @7 z. [" e3 C; d
健择（吉西他滨）+顺铂+阿瓦斯汀 Z* M4 Z2 v1 f8 X( \
Gemzar +Cisplatin + Avastin$ @) n; f2 |% M8 A2 ?: _; C
http://annonc.oxfordjournals.org/content/21/9/1804.full
* T% ?2 j+ @7 v" `% IOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) . p/ x" n! p4 W$ r$ [% i! ^) m8 h; O* t
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
! o% ^3 T% ]2 d' _( cResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. , x8 W# s% x6 ?3 J$ U
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 858)
3 u: T/ M3 W9 y8 p* ^2 e0 z ^
华为网盘附件：
2 G; x4 ]* |$ t1 F' ?4 ]【华为网盘】ava.JPG
6 ~& u4 l$ o: r+ T3 F" d8 m |
显身卡
